1-4 of 4
Cara E Toscan
Close
Sort by
Journal Articles

The AKR1C3-Activated Prodrug, Achm-025, Eradicates Disease in Preclinical Models of Aggressive T-Cell Acute Lymphoblastic Leukemia

Richard B. Lock, Cara E Toscan, Hannah McCalmont, Kathryn Evans, Louise Doculara, Hansen J Kosasih, Andrew J Gifford, Amir Ashoorzadeh, Xiaojing Lin, Toby N Trahair, Charles E De Bock, Adam V Patterson, Jeff B Smaill
Journal: Blood
Blood (2023) 142 (Supplement 1): 4251.
https://doi.org/10.1182/blood-2023-181298
Published: 2023
Journal Articles

Pediatric Preclinical Testing Consortium Evaluation of the MCL1 Inhibitor, AMG 176, Against Xenograft Models of Acute Lymphoblastic Leukemia

Richard B Lock, Kathryn Evans, Ben Watts, Joanna Randall, Cara E Toscan, Eric J Earley, Stephen W Erickson, Brian Belmontes, Philip Wong, Beverly A Teicher, Paul E Hughes, Malcolm A Smith
Journal: Blood
Blood (2022) 140 (Supplement 1): 11690–11691.
https://doi.org/10.1182/blood-2022-159885
Published: 2022
Journal Articles

Pediatric Preclinical Testing Consortium Evaluation of the Novel Anti-Microtubule Drug E7130 in Xenograft Models of Early T-Cell Precursor Acute Lymphoblastic Leukemia

Richard B. Lock, PhD, Kathryn Evans, Connor D Jones, Narimanne El-Zein, Katerina Bendak, PhD, Cara E Toscan, PhD, Chelsea Mayoh, Stephen W Erickson, PhD, Beverly A Teicher, PhD, Malcolm A Smith, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3875.
https://doi.org/10.1182/blood-2019-123867
Published: 2019
Journal Articles

AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemia

Donya Moradi Manesh, Jad El-Hoss, Kathryn Evans, Jennifer Richmond, Cara E. Toscan, Lauryn S. Bracken, Ashlee Hedrick, Rosemary Sutton, Glenn M. Marshall, William R. Wilson, Raushan T. Kurmasheva, Catherine Billups, Peter J. Houghton, Malcolm A. Smith, Hernan Carol, Richard B. Lock
Journal: Blood
Blood (2015) 126 (10): 1193–1202.
https://doi.org/10.1182/blood-2014-12-618900
Published: 2015
Includes: Supplemental data